The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of epigenetic priming using azacitidine prior to neoadjuvant chemotherapy in patients with resectable esophageal and gastric adenocarcinoma.
Bryan J. Schneider
Research Funding - Celgene
Manish A. Shah
Honoraria - Celgene
Allyson J. Ocean
Honoraria - Roche/Genentech
Elizabeta C. Popa
No relevant relationships to disclose
Andrew Schreiner
No relevant relationships to disclose
Paul J. Christos
No relevant relationships to disclose
Alice Mercado
No relevant relationships to disclose
Romae Palmer
No relevant relationships to disclose
Jeffrey L. Port
No relevant relationships to disclose
Nasser K. Altorki
No relevant relationships to disclose
Joseph M Scandura
Research Funding - Celgene